Experimental gene therapy against subcutaneously implanted glioma with a herpes simplex virus-defective vector expressing interferon-γ

Cancer Gene Therapy

Volumn 6, Issue 2, 1999, Pages 147-155

  Kanno, Hiroshi ^a   Hattori, Satoshi ^b   Sato, Hidemitsu ^a   Murata, Hidetoshi ^a   Huang, Fu Hui ^a   Hayashi, Akimune ^a   Suzuki, Noriyuki ^a   Yamamoto, Isao ^a   Kawamoto, Susumu ^c   Minami, Mutsuhiko ^d   Miyatake, Shin Ichi ^e   Shuin, Taro ^f   Kaplitt, Micheal G ^g  

^a Yokohama City University   (Japan)

^b Yokohama City University   (Japan)

^c Yokohama City University   (Japan)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

^e KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

^f KOCHI MEDICAL SCHOOL   (Japan)

^g ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Gene therapy; Glioma; Herpes simplex virus vector; Interferon g

Indexed keywords

GAMMA INTERFERON;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; C3H MOUSE; CERCOPITHECUS; COMPARATIVE STUDY; DEFECTIVE VIRUS; DOSE RESPONSE; GENE THERAPY; GENE VECTOR; GENETICS; GLIOMA; HERPES SIMPLEX VIRUS; METABOLISM; METHODOLOGY; MOUSE; PATHOLOGY; TIME; VERO CELL;

ANIMALS; CERCOPITHECUS AETHIOPS; DEFECTIVE VIRUSES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE THERAPY; GENETIC VECTORS; GLIOMA; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; SIMPLEXVIRUS; TIME FACTORS; VERO CELLS;

EID: 0033093013     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700008     Document Type: Article

References (25)

1. Mahaley MS, Jr, Mettlin C, Natarajan ER, et al. National survey of patterns of care for brain-tumor patients. J Neu-rosurg. 1989;71:826-836.
2. Walker MD, Green SB, Byar DP, et al. Randomized comparison of radiotherapy and nitrosoureas for the treatment of glioma after surgery. N Engl J Med. 1980;303: 1323-1329.
3. Daumas-Duport C, Scheithauer B, OTallon J, et al. Grading of astrocytomas: a simple and reproducible method. Cancer. 1988;62:2152-2165.
4. Oldfield EH, Ram Z, Culver KW, et al. Clinical protocols: gene therapy for the treatment of brain tumors using intra-tumoral transduction with thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther. 1993;4:39-69.
5. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1:938-943.
6. Okada H, Miyamura K, Itoh T, et al. Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene Ther. 1996;3:957-964.
7. Vincent AJ, Esandi MC, Avezaat CJ, et al. Preclinical testing of recombinant adenoviral herpes simplex virus-thymidine kinase gene therapy for central nervous system malignancies. Neurosurgery. 1997;41:442-451.
8. Mizuno M, Yoshida J, Sugita K, et al. Growth inhibition of glioma cells transfected with the human /3-interferon gene by liposomes coupled with a monoclonal antibody. Cancer Res. 1990;50:7826-7829.
9. Ram Z, Walbridge S, Heiss JD, et al. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J Neurosurg. 1994;80:535-540.
10. Sobel RE, Fakhrai H, Schawler D, et al. Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 1995;2: 164-167.
11. Kurzrock R. Interferon-y. In: Galvani DW, Cawley JC, eds. Cytokine Therapy. Cambridge: Cambridge University Press; 1992:131-151.
12. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon y cDNA in mouse neuroblastoma Cl300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA. 1989;86:9456-9460.
13. Gansbacher B, Zier K, Cronin K, et al. Retroviral vector-mediated y-interferon gene transfer into tumor cells generates potent and long-lasting antitumor immunity. Cancer Res. 1990;50:7820-7825.
14. Maruguchi Y, Toda KI, Fjuii K, et al. Survival period of tumor-bearing mice is prolonged after the interferon-y-producing gene transfer. Cancer Lett. 1991;60:41-49.
15. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, et al. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-y gene-inserted tumor cells. J Im-munol. 1993;150:1458-1470.
16. Hock H, Dorsch M, Kunzendorf U, et al. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon-y. Proc Natl Acad Sci USA. 1993;90: 2774-2778.
17. Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther. 1997;4: 222-228.
18. Yu JS, Burwick JA, Dranoff G, Breakefield XO. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-trans-duced tumor cells. Hum Gene Ther. 1997;8:1065-1072.
19. Kaplitt MG, Pfaus JG, Kleopoulous SP, et al. Expression of a functional foreign gene in adult mammalian brain following in vivo transfer via a herpes simplex virus type 1-defective viral vector. Mol Cell Neurosci. 1991;2:320-330.
20. Spaete RR, Frenkel N. The herpes simplex virus amplicon: a new eukaryotic defective-virus cloning-amplifying vector. Cell. 1982;30:295-304.
21. Kwong AD, Frenkel N. Herpes simplex virus amplicon: effect of size on replication of constructed defective genomes containing eukaryotic DNA sequences. J Virol. 1984;51:595-603.
22. Spaete RR, Frenkel N. The herpes simplex virus amplicon: analysis of c/s-acting replication functions. Proc Natl Acad Sci USA. 1985;4:694-698.
23. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-perox-idase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
24. Habu S, Fukui H, Shimamura K, et al. In vivo effects of anti-asialo GM1./Immunol. 1981;127:34-38.
25. Chou J, Kern ER, Whitley RJ, et al. Mapping of herpes simplex virus-1 neurovirulence to y 134.5, a gene nonessential for growth in culture. Science. 1990;250:1262-1266.